Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RGNX – REGENXBIO Inc.

REGENXBIO Inc.
RGNX
$11.14
Name : REGENXBIO Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $563,941,248.00
EPSttm : -3.46
finviz dynamic chart for RGNX
REGENXBIO Inc.
$11.14
3.21%
$0.37

Float Short %

9.86

Margin Of Safety %

Put/Call OI Ratio

0.7

EPS Next Q Diff

-0.19

EPS Last/This Y

1.39

EPS This/Next Y

0.83

Price

11.14

Target Price

31.25

Analyst Recom

1.42

Performance Q

38.73

Relative Volume

0.95

Beta

1.16

Ticker: RGNX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20RGNX12.640.890.443578
2025-10-21RGNX13.090.890.013615
2025-10-22RGNX12.190.770.413916
2025-10-23RGNX12.550.770.353916
2025-10-24RGNX13.040.770.003930
2025-10-27RGNX13.620.760.003954
2025-10-28RGNX13.160.710.004134
2025-10-29RGNX12.830.690.004199
2025-10-30RGNX12.80.680.004241
2025-10-31RGNX12.770.680.004243
2025-11-03RGNX11.990.683.124227
2025-11-04RGNX11.550.720.004379
2025-11-05RGNX11.590.720.064393
2025-11-06RGNX11.180.710.784408
2025-11-07RGNX11.220.710.004440
2025-11-10RGNX11.030.710.114438
2025-11-11RGNX11.560.720.004432
2025-11-12RGNX11.60.710.024445
2025-11-13RGNX11.660.700.094503
2025-11-14RGNX11.510.700.024492
2025-11-17RGNX11.140.700.034490
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20RGNX12.64-11.0266.4-2.28
2025-10-21RGNX13.06-11.0258.1-2.28
2025-10-22RGNX12.19-11.0240.7-2.28
2025-10-23RGNX12.56-11.0257.6-2.28
2025-10-24RGNX13.02-11.0258.3-2.28
2025-10-27RGNX13.64-11.0260.3-2.28
2025-10-28RGNX13.16-11.0246.8-2.28
2025-10-29RGNX12.84-11.0248.1-2.28
2025-10-30RGNX12.82-11.0252.0-2.28
2025-10-31RGNX12.77-11.0251.6-2.28
2025-11-03RGNX11.99-11.0241.9-2.28
2025-11-04RGNX11.52-11.0245.4-2.28
2025-11-05RGNX11.61-11.0253.1-2.28
2025-11-06RGNX11.19-11.0245.7-2.28
2025-11-07RGNX11.21-11.0238.8-2.28
2025-11-10RGNX11.02117.0239.3-2.28
2025-11-11RGNX11.55117.0250.1-3.20
2025-11-12RGNX11.60117.0242.9-3.20
2025-11-13RGNX11.64117.0242.8-3.20
2025-11-14RGNX11.5226.3240.7-3.20
2025-11-17RGNX11.1426.7237.1-3.20
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20RGNX-1.29-0.2510.80
2025-10-21RGNX-1.29-0.2510.80
2025-10-22RGNX-1.29-0.2510.80
2025-10-23RGNX-1.29-0.2510.80
2025-10-24RGNX-1.29-0.2510.80
2025-10-27RGNX-1.29-2.7610.57
2025-10-28RGNX-1.29-2.7610.57
2025-10-29RGNX-1.29-2.7610.57
2025-10-30RGNX-1.29-2.7610.57
2025-10-31RGNX-1.29-2.7610.57
2025-11-03RGNX-1.29-2.3510.57
2025-11-04RGNX-1.29-2.3510.57
2025-11-05RGNX-1.29-2.3510.57
2025-11-06RGNX-1.29-2.3510.57
2025-11-07RGNX-1.29-2.3510.57
2025-11-10RGNX-1.29-2.2610.55
2025-11-11RGNX-1.29-2.2610.55
2025-11-12RGNX-1.29-2.269.83
2025-11-13RGNX-1.29-2.269.83
2025-11-14RGNX-1.29-2.269.81
2025-11-17RGNX-0.84-1.839.86
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.2

Avg. EPS Est. Current Quarter

-0.74

Avg. EPS Est. Next Quarter

-1.39

Insider Transactions

-0.84

Institutional Transactions

-1.83

Beta

1.16

Average Sales Estimate Current Quarter

66

Average Sales Estimate Next Quarter

77

Fair Value

Quality Score

39

Growth Score

40

Sentiment Score

73

Actual DrawDown %

77.8

Max Drawdown 5-Year %

-89.4

Target Price

31.25

P/E

Forward P/E

PEG

P/S

3.5

P/B

3.49

P/Free Cash Flow

EPS

-3.49

Average EPS Est. Cur. Y​

-3.2

EPS Next Y. (Est.)

-2.37

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-110.29

Relative Volume

0.95

Return on Equity vs Sector %

-137.1

Return on Equity vs Industry %

-122.2

EPS 1 7Days Diff

-0.9

EPS 1 30Days Diff

-0.92

EBIT Estimation

237.1
REGENXBIO Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 353
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today
news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance
stock history RGNX – REGENXBIO Inc. invest stock market
stock prices RGNX premarket after hours
ticker RGNX fair value insiders trading